These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
565 related articles for article (PubMed ID: 24700748)
21. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen. Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372 [TBL] [Abstract][Full Text] [Related]
22. Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis. Zheng F; Put S; Bouwens L; Lahoutte T; Matthys P; Muyldermans S; De Baetselier P; Devoogdt N; Raes G; Schoonooghe S J Nucl Med; 2014 May; 55(5):824-9. PubMed ID: 24686780 [TBL] [Abstract][Full Text] [Related]
23. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth. Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065 [TBL] [Abstract][Full Text] [Related]
24. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Viola-Villegas NT; Sevak KK; Carlin SD; Doran MG; Evans HW; Bartlett DW; Wu AM; Lewis JS Mol Pharm; 2014 Nov; 11(11):3965-73. PubMed ID: 24779727 [TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo comparative study of a novel Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375 [No Abstract] [Full Text] [Related]
26. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535 [TBL] [Abstract][Full Text] [Related]
27. Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging. Kimura H; Sampei S; Matsuoka D; Harada N; Watanabe H; Arimitsu K; Ono M; Saji H Bioorg Med Chem; 2016 May; 24(10):2251-6. PubMed ID: 27073053 [TBL] [Abstract][Full Text] [Related]
28. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer. Han D; Wu J; Han Y; Wei M; Han S; Lin R; Sun Z; Yang F; Jiao D; Xie P; Zhang L; Yang AG; Zhao A; Wen W; Qin W Oncotarget; 2016 Sep; 7(37):59471-59481. PubMed ID: 27448970 [TBL] [Abstract][Full Text] [Related]
29. Development and Characterization of Bolzati C; Gobbi C; Ferro-Flores G; Turato S; Ocampo-Garcia B; Carpanese D; Marzano C; Spolaore B; Fracasso G; Rosato A; Meléndez-Alafort L Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203663 [TBL] [Abstract][Full Text] [Related]
30. Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of Pham TT; Hungnes IN; Rivas C; Cleaver J; Firth G; Blower PJ; Sosabowski J; Cook GJR; Livieratos L; Young JD; Pringle PG; Ma MT J Nucl Med; 2024 Jul; 65(7):1087-1094. PubMed ID: 38844360 [TBL] [Abstract][Full Text] [Related]
31. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics. Huynh TT; Feng Y; Meshaw R; Zhao XG; Rosenfeld L; Vaidyanathan G; Papo N; Zalutsky MR Nucl Med Biol; 2024; 134-135():108913. PubMed ID: 38703588 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and Radiolabeling of Glu-Urea-Lys with Hatamabadi D; Joukar S; Shakeri P; Balalaie S; Yazdani A; Khoramjouy M; Mazidi SM; Kobarfard F; Mosayebnia M; Bozorgchami N; Ahmadi M; Ayyoubzadeh SM; Shahhosseini S Cancer Biother Radiopharm; 2023 Sep; 38(7):486-496. PubMed ID: 37578479 [No Abstract] [Full Text] [Related]
35. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Huang L; Gainkam LO; Caveliers V; Vanhove C; Keyaerts M; De Baetselier P; Bossuyt A; Revets H; Lahoutte T Mol Imaging Biol; 2008; 10(3):167-75. PubMed ID: 18297364 [TBL] [Abstract][Full Text] [Related]
36. Preclinical Evaluation of Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
38. Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer. Graham K; Lesche R; Gromov AV; Böhnke N; Schäfer M; Hassfeld J; Dinkelborg L; Kettschau G J Med Chem; 2012 Nov; 55(22):9510-20. PubMed ID: 23025786 [TBL] [Abstract][Full Text] [Related]
39. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Kularatne SA; Wang K; Santhapuram HK; Low PS Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233 [TBL] [Abstract][Full Text] [Related]
40. Synthesis and Evaluation of Li Z; Jiang Y; Ruan Q; Yin G; Han P; Duan X; Zhang J Mol Pharm; 2024 Oct; 21(10):5305-5314. PubMed ID: 39298677 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]